Neuro-Oncology

The UCLA Neuro-oncology Program conducts extensive translational and clinical research focused on individualizing treatments to extend and improve the lives of patients with primary brain tumors. The program faculty members often collaborate with other investigators in the UCLA Brain Tumor Center and are part of the brain cancer SPORE.

Basic and Translational Research:
UCLA Brain Tumor Center Research

Additional Information - Neuro-Oncology Program:
Neuro-Oncology Program
The Lai Lab


Clinical Trials

Neuro-Oncology clinical trials include advanced treatment modalities for brain cancer including targeted therapies, viral therapies, and immunotherapies. Other clinical trials include studies in tumor imaging, quality of care, and neurocognition in collaboration with other researchers at UCLA Health.

For questions on clinical trials, contact:
Emese Filka
Clinical Trial Coordinator
310-794-3521

You may find more information on the following clinical trials offered by our program at ClinicalTrials.gov

UCLA - IRB Number Study Agent Targeted Pathology Diagnosis Trial Phase

#14-000514

Lapatinib with Surgery

Recurrent High-Grade Glioma

Early Phase

#14-000800

MLN0128 with Surgery

Preoperative Recurrent Glioblastoma (GBM)                                          

Pilot Study

#15-001667

ACP-196

Recurrent GBM

Phase 1b/2

#16-000207

Nivolumab vs Temozolomide, with RT

Newly Diagnosed GBM

Phase 3

#16-000365

Temozolomide plus Radiation  Therapy (RT) Combined with Nivolumab

Newly Diagnosed GBM

Phase 2

#16-000464

IL-7 (CYT107)

High Grade Gliomas

Pilot Study

#16-000576

DNX-2401 with Pembrolizumab

1st or 2nd Recurrent GBM or Gliosarcoma

Phase 2

#16-000649

ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide

Newly Diagnosed GBM

Phase 2b/3

#16-001865

Pembrolizumab

Recurrent Malignant Glioma

Pilot Study

#16-001874

Abemaciclib

Recurrent GBM

Phase 2

#17-000338

Avelumab with HFRT

Recurrent GBM transformed from low grade glioma

Phase 2

#17-000756

PT2385

Recurrent GBM

Phase 2

#17-000758

Anti-LAG-3 or Anti-CD137 in Combination with Anti-PD-1

Recurrent GBM

Phase 1

#17-000794

DSP-7888 with Bevacizumab

Recurrent GBM

Phase 2

#17-000998

BGB-290 with Temozolomide and/or RT

Newly Diagnosed GBM or 1st Recurrent GBM

Phase 1b/2

#17-001423

AMG596

Newly Diagnosed GBM or Recurrent GBM

Phase 1

#17-001719

AG120 or AG881, with surgery

Recurrent Grade 2 or 3 Low Grade Glioma

Phase 1


 

Giving: Your gift to the UCLA Neuro-Oncology Program makes a difference.